Eli Lilly Makes 1 Billion Dollar Bet on Opioid-Free Pain Relief with Bold SiteOne Acquisition
On May 27, Eli Lilly announced a strategic move to acquire SiteOne Therapeutics in a deal worth up to $1 billion, underscoring its commitment to expanding non-opioid pain therapies. The deal centers on STC-004, a Nav1.8 inhibitor that’s poised to enter Phase 2 clinical trials.
Nav1.8 is an ion channel critical to pain signal transmission in the peripheral nervous system. By targeting this pathway, STC-004 offers hope for long-term relief from chronic pain without the addiction risks associated with opioids. Lilly will pay $300–400 million upfront, with the remainder tied to regulatory and commercial milestones.
This acquisition strengthens Lilly’s pipeline beyond its current blockbuster drugs like tirzepatide for obesity and diabetes. Notably, Vertex Pharmaceuticals is the only company so far to have secured approval for a NaV1.8 inhibitor (Journavx), after past setbacks in the class.
The path to non-opioid analgesics has been challenging. Vertex halted development of two similar candidates in 2020 before succeeding with one in later trials, though it failed to outperform Vicodin, a traditional opioid.
Lilly has previously ventured into pain treatment, collaborating with Pfizer on tanezumab, a nerve growth factor (NGF) inhibitor. Despite initial promise in treating osteoarthritis, tanezumab was ultimately rejected by regulators over safety concerns.
With the global opioid crisis intensifying, the industry is racing to develop safer, effective alternatives. If STC-004 can continue showing clinical promise, it may become a game-changer for millions suffering from chronic pain.
2026-10-14
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Two Major Chemical Companies Collapse in May as the Global Industry Faces a Broad Downturn
-
Akzo Nobel and Axalta Announce a $25 Billion Merger Deal
-
Clariant and FUHUA Establish Joint Venture to Co-Develop Halogen-Free Flame Retardants
-
SABIC Agri-Nutrients Advances Mega Fertilizer Expansion With 1.2 Million MT/Year Ammonia Plant
-
Sinopec Oilfield Service Chairman Steps Down, Sinopec Shanghai Sales Branch Deputy GM Investigated on Consecutive Days
-
BASF Raises Acid Chloride and Chloroformate Capacity by 30% at Ludwigshafen
-
BASF Sues Apple Over Face Authentication Patents Used in Dozens of iPhones and iPads
-
Ineos Rescues UK's Last Dichloroethane Plant
-
Eurofragance Launches Proprietary Fragrance Ingredient Olivante
-
Huntsman Partners with Wobatek to Expand TPU Distribution
Recommend Reading
-
BASF Battles Market Turmoil as Profits Slide
-
Wanhua Chemical Establishes a RMB 1.488 Billion New Energy Materials Company in Weifang, Further Integrating Green Power and Battery Materials Businesses
-
A Comprehensive Overview of China’s Special Engineering Materials Market: How Should the Industry Rebuild Its Capabilities Amid Growing Downstream Pressure?
-
Shell Polymers Explosion Caused About $95 Million in Damage, U.S. CSB Finds
-
BASF Brings Biomass-Balance Polyols to North America
-
Styrene-Butadiene Rubber Market Trends: Rising First, Then Falling, with High-Level Volatility
-
BDO market in China operates steadily
-
Business Society September 21, 2026 Caustic Soda Trend Analysis: Trend is Bullish
-
This Week Sodium Metabisulfite Prices Stabilize in China (10.20-10.24)
-
Business Society September 20, 2026 Caustic Soda Trend Analysis: Volatile Trading